• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CARs on track in the clinic.

作者信息

Kohn Donald B, Dotti Gianpietro, Brentjens Renier, Savoldo Barbara, Jensen Michael, Cooper Laurence Jn, June Carl H, Rosenberg Steven, Sadelain Michel, Heslop Helen E

机构信息

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California 90095, USA.

出版信息

Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1.

DOI:10.1038/mt.2011.1
PMID:21358705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3048197/
Abstract
摘要

相似文献

1
CARs on track in the clinic.嵌合抗原受体在临床中步入正轨。
Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1.
2
Gene-modified hematopoietic stem cells for cancer immunotherapy.用于癌症免疫治疗的基因修饰造血干细胞
Hum Vaccin Immunother. 2014;10(4):982-5. doi: 10.4161/hv.27637. Epub 2014 Jan 9.
3
Immunotherapy with chimeric antigen receptors for multiple myeloma.用于多发性骨髓瘤的嵌合抗原受体免疫疗法。
Discov Med. 2014 Jan;17(91):37-46.
4
Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.用 CD19 特异性嵌合抗原受体修饰造血干细胞/祖细胞作为癌症免疫治疗的新方法。
Hum Gene Ther. 2013 Oct;24(10):824-39. doi: 10.1089/hum.2012.202.
5
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.嵌合抗原受体（CAR）疗法需要驾驶执照吗？采用嵌合抗原受体重定向T细胞的过继性细胞疗法已引发严重不良事件。
Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131.
6
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.采用自体嵌合抗原受体修饰的肿瘤靶向T细胞对B细胞恶性肿瘤进行过继性免疫治疗。
Discov Med. 2010 Apr;9(47):277-88.
7
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.基于广泛中和抗体的HIV-1特异性嵌合抗原受体
J Virol. 2016 Jul 11;90(15):6999-7006. doi: 10.1128/JVI.00805-16. Print 2016 Aug 1.
8
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.抗体修饰的 T 细胞：CARs 在血液恶性肿瘤中占据主导地位。
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
9
The pharmacology of second-generation chimeric antigen receptors.第二代嵌合抗原受体的药理学
Nat Rev Drug Discov. 2015 Jul;14(7):499-509. doi: 10.1038/nrd4597.
10
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.嵌合抗原受体下游细胞内信号传导的评估
PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.

引用本文的文献

1
Zebrafish as a Model for Translational Immuno-Oncology.斑马鱼作为转化免疫肿瘤学的模型
J Pers Med. 2025 Jul 11;15(7):304. doi: 10.3390/jpm15070304.
2
CAR-T cell therapy for cancer: current challenges and future directions.用于癌症治疗的嵌合抗原受体T细胞疗法：当前挑战与未来方向
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
3
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.嵌合抗原受体设计的重大进展和演变。
Int J Mol Sci. 2024 Nov 13;25(22):12201. doi: 10.3390/ijms252212201.
4
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.抗CD19嵌合抗原受体T细胞免疫疗法治疗复发/难治性大B细胞淋巴瘤患者的有效性和安全性：一项系统评价和荟萃分析
Front Pharmacol. 2022 Apr 25;13:834113. doi: 10.3389/fphar.2022.834113. eCollection 2022.
5
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15-16 February 2019, Doha, Qatar.第一届锡德拉医学国际研讨会会议记录：“癌症免疫治疗中的工程化免疫细胞（EICCI）：从发现到现成产品开发”，2019 年 2 月 15-16 日，卡塔尔多哈。
Front Immunol. 2021 Jan 14;11:589381. doi: 10.3389/fimmu.2020.589381. eCollection 2020.
6
Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.用于过继性T细胞治疗的GPC3和EGFR双靶点嵌合抗原受体T细胞的开发
Am J Transl Res. 2021 Jan 15;13(1):156-167. eCollection 2021.
7
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.SITC 癌症免疫治疗资源文件：生物标志物发现领域的指南针。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-000705.
8
Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.嵌合抗原受体表达 T 细胞的癌症免疫治疗：临床癌症中心的现在和未来需求。
Front Immunol. 2020 Oct 30;11:565236. doi: 10.3389/fimmu.2020.565236. eCollection 2020.
9
Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach.少即是多：使用数学指导方法减少小鼠模型中给予的嵌合抗原受体 T 细胞数量。
Cancer Immunol Immunother. 2020 Jul;69(7):1165-1175. doi: 10.1007/s00262-020-02516-9. Epub 2020 Mar 4.
10
The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.癌症干细胞/癌症起始细胞与肿瘤微环境之间的相互作用：免疫疗法有效靶向这些细胞的关键缺失环节。
Cancer Microenviron. 2019 Dec;12(2-3):133-148. doi: 10.1007/s12307-019-00233-1. Epub 2019 Nov 22.

本文引用的文献

1
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.经体外工程化 T 细胞治疗的患者对转基因和逆转录病毒载体的免疫反应。
Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.
2
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.自体 T 细胞经基因工程改造后识别 CD19，用于治疗患者，可消除 B 细胞系细胞并使淋巴瘤消退。
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
3
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.采用基因工程 T 细胞的过继免疫疗法：嵌合抗原受体细胞外部分的 IgG1 Fc“间隔区”结构域的修饰可避免“脱靶”激活和非预期固有免疫反应的启动。
Gene Ther. 2010 Oct;17(10):1206-13. doi: 10.1038/gt.2010.91. Epub 2010 Jun 17.
4
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.通过引入肿瘤特异性嵌合抗原受体来改变 T 细胞的特异性。
Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3.
5
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.用白细胞介素 15 和自杀基因工程改造 CD19 特异性 T 淋巴细胞，以增强其抗淋巴瘤/白血病效应和安全性。
Leukemia. 2010 Jun;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub 2010 Apr 29.
6
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.采用基因靶向自体T细胞治疗慢性淋巴细胞白血病：一项I期临床试验中意外不良事件的病例报告
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
7
Safer CARS.更安全的汽车碰撞减速度限制系统（CARS）
Mol Ther. 2010 Apr;18(4):661-2. doi: 10.1038/mt.2010.42.
8
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.抗转基因排斥反应导致过继转移的 CD20/CD19 特异性嵌合抗原受体重定向 T 细胞在人体内的持久性减弱。
Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19.
9
Building better chimeric antigen receptors for adoptive T cell therapy.构建更好的嵌合抗原受体用于过继性 T 细胞疗法。
Curr Gene Ther. 2010 Apr;10(2):77-90. doi: 10.2174/156652310791111001.
10
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.嵌合抗原受体识别 ERBB2 的 T 细胞给药后严重不良事件的病例报告。
Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23.